Benabdallah Ghita, Benkirane Raja, Khattabi Asmae, Edwards I Ralph, Bencheikh Rachida Soulaymani
Moroccan Poison Control and Pharmacovigilance Centre, Rabat, Morocco.
Int J Risk Saf Med. 2011;23(1):17-29. doi: 10.3233/JRS-2011-0513.
This study assesses the ability of Pharmacovigilance Centres (PVCs) to detect medication errors (ME) and to proceed to building Patient Safety (PS) via their information networks and to underline the limits for this challenge.
This was an exploratory study conducted in PVCs members of the World Health Organization International Drug Monitoring network. A questionnaire specifically designed for the needs of the study was sent to a network via a confidential email system. The questionnaire asked for information, progress and improvement made by PVCs in PS and ME.
Among the 88 countries, 21 answered. Reporting of Adverse Drug Reactions (ADRs) by health care professionals (HCP) is mandatory for 42% of PVCs. 100% of countries receive reports from HCP, 66% from patients and 24% from PCCs. ADRs reports are received by all communications means. There is an heterogeneity between countries regarding PVCs and PS activities. Among them, 4 PVCs have the prime activity of PS organization.
PVCs are able to detect and analyze ME. There is a need to coordinate efforts between countries to optimize ME detection, and its analysis. Bridges need to be built linking PVCs, PCCs and PS organizations in order to avoid duplication of workload.
本研究评估药物警戒中心（PVCs）通过其信息网络检测用药错误（ME）并推进患者安全（PS）建设的能力，并强调这一挑战的局限性。
这是一项针对世界卫生组织国际药物监测网络的PVCs成员开展的探索性研究。通过保密电子邮件系统向该网络发送了一份专门为研究需求设计的问卷。问卷询问了PVCs在患者安全和用药错误方面的信息、进展及改进情况。
在88个国家中，21个国家进行了回复。42%的PVCs要求医疗保健专业人员（HCP）强制报告药品不良反应（ADR）。100%的国家收到来自HCP的报告，66%来自患者，24%来自初级保健中心（PCCs）。通过所有通信方式均可收到ADR报告。各国在PVCs和患者安全活动方面存在异质性。其中，4个PVCs的主要活动是患者安全组织。
PVCs能够检测和分析用药错误。各国需要协调努力，以优化用药错误的检测及其分析。需要搭建连接PVCs、PCCs和患者安全组织的桥梁，以避免工作负荷的重复。
